申请人:Eisai R&D Management Co., Ltd.
公开号:US08338407B2
公开(公告)日:2012-12-25
The present invention relates to a fused aminodihydrothiazine derivative of formula (I):
wherein
X is hydrogen or fluorine;
A is CH or N;
Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C≡N;
and pharmaceutically acceptable salts thereof;
which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
本发明涉及一种公式(I)的融合氨基二氢噻嗪衍生物:
其中X为氢或氟;A为CH或N;Y为甲基,乙基,单氟甲基,二氟甲基,三氟甲基,二氟乙基,甲氧基,乙氧基,甲氧甲基或—C≡N;以及其药学上可接受的盐。该化合物具有Aβ产生抑制作用或BACE1抑制作用,并且可用作预防或治疗由Aβ引起的神经退行性疾病,其以阿尔茨海默型痴呆为代表。